Highest-materiality recent filing
NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M
Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.
Preliminary Q4 2025 revenue ~$190M (+11% YoY); full-year 2025 revenue ~$727M (+10% YoY).
NeoGenomics appoints Jack Kenny to board; Dr. Alison Hannah departs after 10 years
Dr. Alison Hannah resigns from NeoGenomics board effective Dec 31, 2025, after over 10 years of service.
NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M
Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.
Director Elizabeth Floegel resigns from NeoGenomics Board effective August 5, 2025
Elizabeth Floegel resigned from the Board of Directors effective August 5, 2025.
NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance
Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).
NeoGenomics appoints Merck oncology head Dr. Marjorie Green to board
Dr. Marjorie C. Green appointed to NeoGenomics board effective June 19, 2025; board expands from 9 to 10 members.
NeoGenomics shareholders approve 4.325M share increase to 2023 Equity Plan, all directors re-elected
Amendment to 2023 Equity Incentive Plan approved: +4.325M shares, 1-year minimum vesting, no liberal share recycling.
On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.
Max materiality 0.78 · Median 0.65 · Most common event earnings